Literature DB >> 7696113

Oral pulse therapy with vitamin D3 for control of secondary hyperparathyroidism.

S Feinstein1, N Algur, A Drukker.   

Abstract

Twelve dialysis patients received oral pulse therapy with 1-alpha-hydroxyvitamin D3 in a dose of 0.1 microgram/kg body weight twice weekly and daily calcium carbonate (1.5-3.5 g) for a period of 8-12 months. This treatment was very effective in suppressing secondary hyperparathyroidism without causing hypercalcaemia and/or hyperphosphataemia.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7696113     DOI： 10.1007/bf00869102

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  9 in total

1.  Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: preliminary observations.

Authors:  K J Martin; H S Ballal; D T Domoto; S Blalock; M Weindel
Journal:  Am J Kidney Dis       Date:  1992-06       Impact factor: 8.860

2.  Intermittent and continuous exposure to 1,25(OH)2D3 have different effects on growth plate chondrocytes in vitro.

Authors:  G Klaus; B König; U Hügel; E Ritz; O Mehls
Journal:  Kidney Int       Date:  1993-10       Impact factor: 10.612

3.  Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.

Authors:  R W Chesney; A Hamstra; D K Jax; R B Mazess; H F DeLuca
Journal:  Contrib Nephrol       Date:  1980       Impact factor: 1.580

4.  The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.

Authors:  Y Tsukamoto; M Nomura; Y Takahashi; Y Takagi; A Yoshida; T Nagaoka; K Togashi; R Kikawada; F Marumo
Journal:  Nephron       Date:  1991       Impact factor: 2.847

5.  Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental renal hyperparathyroidism.

Authors:  H Reichel; A Szabo; J Uhl; S Pesian; A Schmutz; H Schmidt-Gayk; E Ritz
Journal:  Kidney Int       Date:  1993-12       Impact factor: 10.612

6.  25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity.

Authors:  C B Langman; A T Mazur; R Baron; M E Norman
Journal:  J Pediatr       Date:  1982-05       Impact factor: 4.406

7.  Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

Authors:  E Slatopolsky; C Weerts; J Thielan; R Horst; H Harter; K J Martin
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

8.  Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function.

Authors:  G Hercz; Y Pei; C Greenwood; A Manuel; C Saiphoo; W G Goodman; G V Segre; S Fenton; D J Sherrard
Journal:  Kidney Int       Date:  1993-10       Impact factor: 10.612

9.  Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.

Authors:  R H Mak; C Turner; T Thompson; H Powell; G B Haycock; C Chantler
Journal:  Br Med J (Clin Res Ed)       Date:  1985-09-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.